Market Place
Sourcing Support
Sobi to Present New Immunology Data at ACR Convergence 2024
07 Nov 2024 //
GLOBENEWSWIRE
Emapalumab Data in Macrophage Activation Syndrome at ACR
30 Oct 2024 //
PR NEWSWIRE
Sobi Emapalumab Fda Fast Track: For Macrophage Activation Syndrome
24 May 2024 //
GLOBENEWSWIRE
Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab
04 Apr 2023 //
GLOBENEWSWIRE
Gamifant (emapalumab) recommended for approval in China for HLH
25 Feb 2022 //
PRNEWSWIRE
Emapalumab submission in China for primary HLH
10 Dec 2020 //
PRNEWSWIRE
The CHMP has adopted a negative opinion for emapalumab in Europe
13 Nov 2020 //
PRESS RELEASE
Sobi bets $250M cash, about $1B in milestones for rights to a C3 therapy
28 Oct 2020 //
ENDPTS
Sobi to refile Gamifant following CHMP rejection
27 Jul 2020 //
PHARMATIMES
EMA: Thumbs up for 11, down for 2 new medicines
25 Jul 2020 //
RAPS
Sobi`s high-priority rare disease drug runs into a wall at EMA
24 Jul 2020 //
ENDPTS
Results From Pivotal Ph2/3 Study of Emapalumab in Patients With Primary HLH
07 May 2020 //
PRNEWSWIRE
Sobi buys rare-disease drug emapalumab, zooms in on hematology and immunology
13 Jun 2019 //
REUTERS
Sobi Acquires Emapalumab and Related Assets
12 Jun 2019 //
PR NEWSWIRE
Sobi to buy Novimmune R&D assets, lay off 90 staff
12 Jun 2019 //
FIERCE BIOTECH
With Gamifant launch rolling, Sobi unveils more data backing the rare disease med
03 Dec 2018 //
FIERCE PHARMA
Novimmune`s Biological Emapalumab-Lzsg Receives Supplemental Approval in US
20 Nov 2018 //
FDA
Sobi’s $50M bet on a rare disease drug pays off with a quick FDA nod
20 Nov 2018 //
ENDPTS
Sobi signs $450M deal for rare disease drug emapalumab, boosting I/O pipeline
21 Jul 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.